Skip to content
DataLookout
Menu

NCT07825688

TxAccess and Dd-cfDNA for Improved Care of Patients With Delayed Graft Function

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Start date pushed from Sep 15, 2026 to Nov 15, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Delayed Graft Function (DGF) severity, defined as time to freedom from dialysis
Timeframe: through 90 days post-transplant

Secondary (6)

Allograft biopsy rate
Health Care Resource Utilization (hospital length of stay)
Health Care Resource Utilization (readmission rate)
Health Care Resource Utilization (days in intensive care unit)
Dialysis utilization
Show 1 moreShow less
Health care related quality of life

Arms and interventions

TxAccess Intervention ArmExperimental

Participants receive standard post-transplant care with deployment of the TxAccess platform and dd-cfDNA monitoring.

Devices: TxAccess

Diagnostic tests: Donor-Derived Cell-Free DNA (dd-cfDNA)